Novavax Inc (NVAX)

Founded. Novavax was established in 1987 and spent much of its early life as a preclinical immunology company working on recombinant protein technology and vaccine candidates. The company burned capital for decades with limited commercial revenue, typical of pre-approval biotech. In 2020, the COVID-19 pandemic created an urgent market demand for new vaccines, and Novavax’s NVX-CoV2373 candidate moved rapidly through development and regulatory review. The company received its first emergency use authorizations in late 2021 and full regulatory approvals across multiple countries in 2022.

The technology. Novavax uses recombinant protein technology to create vaccines. Recombinant protein vaccines are engineered in the laboratory — the actual viral protein is manufactured without the virus itself — and then combined with an adjuvant (a substance that amplifies the immune response). This is different from mRNA vaccines, which instruct cells to manufacture the viral protein internally. Recombinant protein is an older, well-understood approach with a long safety track record, though it is more manufacturing-intensive and slower to produce at scale than mRNA.

The path to revenue. For decades Novavax had minimal revenue and ran on investor capital. The COVID-19 vaccine changed that dramatically. Governments and international health organizations ordered hundreds of millions of doses, generating substantial revenue. The company also received manufacturing grants and regulatory support from multiple countries. This sudden cash influx was a pivot moment: Novavax moved from pure cash burn to a cash-generative company, though still with elevated risk.

Current business. The company now operates in two main areas. The first is its COVID-19 vaccine, which is approved and available in many countries. Revenue depends on government procurement, global demand (which has declined sharply from the peak pandemic rush), and competition from Pfizer, Moderna, and other COVID vaccine makers. This business is real but contracting as the acute phase of the pandemic recedes.

The second area is pipeline vaccines, principally a combined COVID-and-influenza vaccine and standalone influenza vaccines. These are in various stages of development and clinical testing. If approved, they could generate material revenue, but approval is not assured, and timelines are uncertain.

The capital picture. Novavax burned cash for decades before 2020, surviving through successive rounds of venture capital and public stock offerings. COVID vaccine revenue provided a cash windfall that substantially improved the balance sheet and funded development. The company received substantial government grants and prepayments for vaccine doses from governments worldwide, which accelerated its transformation from perpetually cash-strapped biotech to a company with material operating cash flow. However, the company still has meaningful development costs, manufacturing infrastructure to maintain, and regulatory risks ahead. Profitability depends on sustained demand for the COVID vaccine (currently declining) or successful commercialization of pipeline products (unproven). The balance sheet remains under pressure as competing vaccines erode Novavax’s market share and as the company must continue investing in pipeline programs without guaranteed returns.

The risks. A biotech company like Novavax is binary by nature. Clinical trials can fail. Regulatory authorities can deny approval. Manufacturing problems can emerge. Approved vaccines can face competition that undercuts pricing and captures market share. The recombinant protein approach, while well-established, has not proven as cost-effective at scale as mRNA manufacturing, which creates a structural disadvantage against Pfizer and Moderna. If the COVID vaccine remains the primary revenue driver and demand continues to contract, and if pipeline products do not reach the market or underperform commercially, the company could face a sharp decline in cash generation and return to dependence on capital markets. Conversely, successful approval of combination vaccines or other candidates would create new revenue streams and justify the company’s continued operation.

How to research Novavax. Start with the company’s 10-K filing (SEC CIK 0001000694), which details revenue by vaccine product, cost of goods sold, research and development expenses, and the structure of government contracts and advance purchase agreements. The quarterly earnings calls provide real-time updates on demand trends for the COVID vaccine, manufacturing capacity utilization, and progress on clinical programs. Pay attention to any updates on combination vaccines or other pipeline candidates; clinical trial results are often disclosed in press releases and regulatory filings.

Key metrics to track include revenue from the COVID vaccine (is it stabilizing or accelerating downward?), gross margins on vaccine sales (are manufacturing costs coming down as efficiency improves?), cash burn rate on research and development (how much is being spent on pipeline programs?), and cash position (how long will existing cash last if revenue declines sharply?). Compare Novavax’s manufacturing capacity and production timelines to those of Pfizer, Moderna, and other competitors to assess competitive positioning.

Investment considerations. Novavax’s story is one of a classic biotech that bet on a particular technology, endured decades of losses, and then benefited from a pandemic-driven opportunity. Whether the company becomes a durable vaccine manufacturer or reverts to cash burn depends on whether it can sustain revenue and launch successful new products — both uncertain. The company’s ability to develop and commercialize combination vaccines and other candidates will determine its long-term viability. Any slowdown in cash generation without offset by new product revenue could force the company back into capital-raising mode, diluting existing shareholders.